We are live on ! Find out more
ASBP

Aspire Biopharma
ASBP

3 hedge funds and large institutions have $90.4K invested in Aspire Biopharma in 2024 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.01% less ownership

Funds ownership: 0.02% → 0% (-0.01%)

82% less funds holding

Funds holding: 17 → 3 (-14)

88% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 16

100% less capital invested

Capital invested by funds: $18.1M → $90.4K (-$18M)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
3
Holders Change
-14
Holders Change %
-82.35%
% of All Funds
0.04%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
2
Increased
–
Reduced
1
Closed
16
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CA
Crossingbridge Advisors
New York
+$940K
2
UBS Group
UBS Group
Switzerland
+$13.6K

Top Sellers

Rank Fund Capital Flow
1
FTCM
Fir Tree Capital Management
New York
-$2.35M
2
PC
Periscope Capital
Ontario, Canada
-$1.93M
3
AI
Arena Investors
New York
-$1.66M
4
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
-$1.66M
5
AA
AQR Arbitrage
Connecticut
-$1.65M
Name Holding Trade Value Shares
Change 		Change in
Stake
CS
1
Clear Street
New York
$81.7K -$490K -36 -86%
UBS Group
2
UBS Group
Switzerland
$8.75K +$13.6K +1 New
FTCM
3
Fir Tree Capital Management
New York
– -$2.35M -177 Closed
PC
4
Periscope Capital
Ontario, Canada
– -$1.93M -146 Closed
AA
5
AQR Arbitrage
Connecticut
– -$1.65M -125 Closed
AI
6
Arena Investors
New York
– -$1.66M -125 Closed
EAM
7
Exos Asset Management
New York
– -$1.65M -125 Closed
Hudson Bay Capital Management
8
Hudson Bay Capital Management
Connecticut
– -$1.66M -125 Closed
LP
9
LMR Partners
United Kingdom
– -$1.65M -125 Closed
FTCM
10
First Trust Capital Management
Illinois
– -$1.41M -107 Closed
CAC
11
Cowen and Company
New York
– -$1.3M -98 Closed
FPA
12
First Pacific Advisors
California
– -$628K -47 Closed
GCL
13
Glazer Capital LLC
New York
– -$439K -33 Closed
QL
14
Quarry LP
New York
– -$400K -30 Closed
WCMNY
15
Westchester Capital Management (New York)
New York
– -$397K -30 Closed
TCM
16
Tuttle Capital Management
Connecticut
– -$187K -14 Closed
RCM
17
Robinson Capital Management
Michigan
– -$114K -8 Closed
TI
18
Tidal Investments
Wisconsin
– -$112K -8 Closed
BlackRock
19
BlackRock
New York
– -$3.31K – –
CA
20
Crossingbridge Advisors
New York
– +$940K +69 New

ASBP Hedge Fund Activity: Q2 2024 in Review

3 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Aspire Biopharma (ASBP) for Q2 2024, worth a combined $90.4K — down 100% from $18.1M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of ASBP and 2 opened new positions — a net loss of 14 holders — while 1 trimmed existing stakes and 0 added.

The largest buyer was Crossingbridge Advisors, opening a new position worth an estimated $940K. The largest seller was Fir Tree Capital Management, exiting entirely with an estimated $2.35M sold.

  • 3 institutional investors held Aspire Biopharma (ASBP) as of Q2 2024, down from 17 in Q1 2024.
  • Funds reported $90.4K of Aspire Biopharma stock for Q2 2024, down 100% quarter-over-quarter.
  • 2 funds opened new Aspire Biopharma positions in Q2 2024 and 16 closed out, a net change of -14 holders.
  • The largest Aspire Biopharma buyer in Q2 2024 was Crossingbridge Advisors, an estimated $940K added.
  • The largest Aspire Biopharma seller in Q2 2024 was Fir Tree Capital Management, an estimated $2.35M sold.

Based on aggregated 13F filings for Q2 2024.